FibroGen/FGEN

$1.31

0.76%
-
1D1W1MYTD1YMAX

About FibroGen

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.

Ticker

FGEN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Thane Wettig

Employees

486

Headquarters

San francisco, United States

FibroGen Metrics

BasicAdvanced
$128.4M
Market cap
-
P/E ratio
-$2.93
EPS
0.82
Beta
-
Dividend rate
$128.4M
0.82454
$20.90
$0.33
2.8M
1.523
1.332
-53.3%
-55.51%
-119.42%
0.869
4.99%
6.75%
-5.72%

What the Analysts think about FibroGen

Analyst Ratings

Majority rating from 3 analysts.
Sell

Price Targets

Average projection from 2 analysts.
33.59% upside
High $2.00
Low $1.50
$1.31
Current price
$1.75
Average price target

FibroGen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-207.38% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$27.1M
-32.42%
Net income
$-56.2M
-11.64%
Profit margin
-207.38%
30.76%

FibroGen Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 34.12%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.81
-$0.90
-$0.65
-$0.57
-
Expected
-$0.75
-$0.70
-$0.68
-$0.43
-$0.42
Surprise
7.52%
27.96%
-4.41%
34.12%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for FibroGen stock?

FibroGen (FGEN) has a market cap of $128.4M as of April 16, 2024.

What is the P/E ratio for FibroGen stock?

The price to earnings (P/E) ratio for FibroGen (FGEN) stock is 0 as of April 16, 2024.

Does FibroGen stock pay dividends?

No, FibroGen (FGEN) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next FibroGen dividend payment date?

FibroGen (FGEN) stock does not pay dividends to its shareholders.

What is the beta indicator for FibroGen?

FibroGen (FGEN) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the FibroGen stock price target?

The target price for FibroGen (FGEN) stock is $1.75, which is 33.59% above the current price of $1.31. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell FibroGen stock

Buy or sell FibroGen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing